Physician profile
Paymon Nourparvar
NPI 1750671988
$2,860.26
in general payments reported to CMS, 2019-2025
29 companies · $296 in 2025
The $296 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,584 · 2020: $235 · 2021: $57.77 · 2022: $269 · 2023: $90.35 · 2024: $328 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,429.91 | 2019-2023 | Da Vinci Surgical System |
| Astellas Pharma US INC | $353.85 | 2019-2024 | Xtandi |
| Myriad Genetic Laboratories, INC. | $100.88 | 2022-2025 | Prolaris |
| Boston Scientific Corporation | $95.44 | 2022-2025 | Spaceoar Vue System - 10ml, Spaceoar System |
| Abbvie INC. | $78.69 | 2019-2024 | |
| Stryker Corporation | $68.00 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $67.22 | 2024 | Bard Urinary Drainage Bag |
| Dendreon Pharmaceuticals LLC | $54.86 | 2024 | Provenge |
| Edap Technomed INC | $54.00 | 2024 | |
| Olympus America INC. | $51.48 | 2020-2021 | |
| Procept Biorobotics Corporation | $46.06 | 2025 | |
| Blue Earth Diagnostics | $45.38 | 2019 | |
| Calyxo, INC. | $41.15 | 2024-2025 | Cvac Aspiration System |
| Endo Pharmaceuticals INC. | $37.97 | 2019-2020 | |
| Agiliti Surgical, INC. | $32.05 | 2023 | Trinity, Sonablate, Soltive |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $30.96 | 2021 | |
| Janssen Biotech, INC. | $29.52 | 2022 | |
| Endo USA, INC. | $27.19 | 2025 | Aveed, Xiaflex |
| Merck Sharp & Dohme LLC | $25.08 | 2024 | Welireg, Keytruda |
| Innovation Technologies INC | $24.94 | 2025 | Irrisept |
| Coloplast Corp | $24.65 | 2024 | |
| Axonics, INC. | $21.80 | 2023 | Axonics, Bulkamid |
| Pfizer INC. | $21.47 | 2025 | |
| Ferring Pharmaceuticals INC. | $21.28 | 2025 | Adstiladrin |
| Smith+Nephew, INC. | $20.60 | 2025 | Stravix |
| Bayer Healthcare Pharmaceuticals INC. | $16.41 | 2022 | |
| Travere Therapeutics, INC. | $13.95 | 2020-2021 | |
| Laborie Medical Technologies Corp. | $12.81 | 2025 | |
| Therapeuticsmd, INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paymon Nourparvar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.